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Key Points: 
 The addition of panobinostat to azacitidine increased composite complete responses but not 
median overall survival or timetoprogression.   
 Further dose or schedule optimization is warranted to improve the risk/benefit profile of 
panobinostat in combination with azacitidine. 
 
Abstract 
Treatment with azacitidine (AZA), a demethylating agent, significantly prolonged median overall survival 
vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival 
with monotherapy is <2 years, novel agents are needed that further improve outcomes. Preclinically, the 
potent pan-deacetylase inhibitor panobinostat(PAN) acted synergistically with demethylating agents. 
This phase 1b/2b trial (n = 113 patients) was designed to determine maximum tolerated dose (MTD) or 
recommended phase 2 dose (RP2D) of PAN+AZA (phase 1b) and to evaluate early efficacy and safety of 
PAN+AZAvsAZAmonotherapy(phase 2b) in patients with higher-risk MDS, chronic myelomonocytic 
leukemia (CMML), or oligoblastic acute myeloid leukemia (AML) with < 30% blasts. The MTD was not 
reached; the RP2D was determined to be PAN30 mg plusAZA 75 mg/m2. In phase 2b, a higher proportion 
of patients in the PAN+AZA arm achieved a composite complete response (complete response + 
morphologic complete response with incomplete blood count + bone marrow complete response 
(27.5% [95% CI, 14.6%-43.9%]) compared with AZA alone (14.3%  [95% CI, 5.4%-28.5%]). However, no 
significant difference was observed in overall survival (1-year survival rate: PAN+AZA 60% [95% CI, 50%-
80%]; AZA 70% [95% CI, 50%-80%]) or timetoprogression (probability at 12 months: PAN+AZA 70% [95% 
CI, 40%-90%]; AZA 70% [95% CI, 40%-80%]). Additionally, there were higher rates of grade 3/4 adverse 
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events (97.4% vs 81.0%) and on-treatment deaths (13.2% vs 4.8%) in the PAN+AZA arm. Further dose or 
schedule optimization is warranted to improve the risk/benefit profile of this regimen.  
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Introduction 
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid disorders characterized 
by severe cytopenias and dysplasias in one or more myeloid lineages. Subclassification of MDS according 
to several prognostic scoring systems identifies patients at substantial risk for transformation to acute 
myeloid leukemia (AML) that is generally refractory to standard treatment.1 MDS remains incurable 
without stemcell transplant, but the advanced age of patients restricts the number eligible for such 
therapy.2 Azacitidine (AZA), the current standard, front-line therapyfor higher-risk MDS, significantly 
prolonged overall survival (OS) in these patients and has shown clinical benefit in those with AML.3-5 
However, response rates with AZA therapy are, in general, < 30%6,7 and of limited durability, with all 
nontransplanted patients eventually progressing or dying, highlighting the significant need for novel 
agents with the potential to improve both response rates and duration of responses.  
Panobinostat (PAN) is a potent pan-deacetylase inhibitor (DACi) recently approved in the United States 
for patients with multiple myeloma.8PAN modulates the acetylation of histone proteins and protein 
chaperones in malignant cells. The epigenetic regulation by PAN is primarily mediated through the 
inhibition of class I histone deacetylase enzymes leading to increased histone acetylation, relaxation of 
chromatin, and alteration of gene expression, including that of tumor suppressor genes.9 In a phase 1a/2 
study of oral PAN in patients with advanced hematologic malignancies, a manageable safety profile was 
established, but only modest efficacy was demonstrated in patients with AML or MDS.10 
In recent years, the involvement of epigenetic processes in the pathogenesis of MDS and the 
transformation to AML has been extensively studied. Several preclinical and clinical studies have 
demonstrated hypermethylation of CpG islands at the promoter regions of a number of genes.11 
Additionally, epigenetic silencing of tumor suppressor genes in MDS, potentially mediated through 
dysregulated histone acetylation, has been associated with transformation to AML and poor 
5 
 
prognosis.12That both AZA and DACi modulate aberrant gene expression by different mechanisms 
suggests that they may act synergistically in MDS and AML. A limited number of clinical trials 
investigating the combination of DACi and demethylating agents have been fully reported, but early-
phase clinical trials of the combination of AZA and a number of DACi’s have shown promising response 
rates.13-16 As PAN is among the most potent DACi in clinical development,17 we hypothesized that the 
combination of PAN and AZA could show clinical benefitover AZA monotherapy. Preclinically, synergy of 
PAN and demethylating agents has been established in primary AML cells, with the combination of PAN 
and decitabine leading to a significant reduction in AML cell viability compared with either agent alone.18 
On the basis of these data, the current phase 1b/2b study was designed to determine the maximum 
tolerated dose (MTD) or recommended phase 2 dose (RP2D), and the early efficacy and safety, of PAN in 
combination with AZA in patients with high-risk MDS, oligoblastic AML, or chronic myelomonocytic 
leukemia (CMML).  
Methods 
Patients 
Adult patients (aged ≥ 18 years) with International Prognostic Scoring System (IPSS) intermediate-2 or 
high-risk MDS, CMML, or AML with multilineage dysplasia and ≤ 30% bone marrow blasts who were not 
planning to undergo hematopoietic stem cell transplant were enrolled. Key inclusion criteria were an 
Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2 and adequate hepatic and renal 
function. Patients with therapy-related MDS or AML, relapsed/refractory AML, clinical symptoms of 
central nervous system leukemia, or impaired cardiac function were excluded. Additionally, patients 
who had received prior treatment with a DACi, AZA, or decitabine, or who were currently receiving a 
drug known to prolong the QT interval that could not be terminated, were not eligible. The study 
protocol was reviewed by theindependent ethics committee or institutional review board at each 
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center, and written informed consent was obtained from each patient prior to any screening 
procedures. 
Study Design  
This was an open-label, multicenter international phase 1b/2b study. In phase 1b, the primary objective 
was determination of the MTD or RP2D of PAN in combination with AZA (Figure 1). Other objectives 
included early analyses of the safety and efficacy of the regimen. Patients were enrolled in escalating 
dose cohorts consisting of ≥ 3 patients each. The starting dose of PAN was 20 mg administered orally on 
days 3, 5, 8, 10, 12, and 15 in combination with AZA75 mg/m2administered on days 1 to 7 in 4-week 
cycles. Successive cohorts received escalating doses of PAN until determination of MTD or RP2D. Dose 
reductions or interruptions were permitted, but the PAN dose was not to decrease below 10 mg. 
Patients were evaluated for dose-limiting toxicities (DLTs), and dose escalation was guided by an 
adaptive Bayesian logistic regression model (BLRM). The MTD could not be declared until ≥ 9 patients 
were evaluated at the dose level in question.  
Upon determination of the MTD or RP2D defined in phase 1b, an additional 80 patients were to be 
enrolled in the phase 2b portion and randomly assigned in a 1:1 ratio to receive either the MTD/RP2D of 
PAN plus AZA (PAN+AZA) or single-agent AZA on a treatment schedule identical to that from phase 1b. 
The primary objective of phase 2b was to assess the early efficacy of PAN at the MTD/RP2D in 
combination with AZA vs AZA alone through the assessment of composite complete response (complete 
response [CR] + morphologic complete response with incomplete blood count [CRi] + bone marrow 
complete response [BM-CR]). Secondary objectives included efficacy assessment of clinical responses 
other than composite CR, 1-year survival, time to progression, and assessment of safety in comparison 
with single-agent AZA.19,20 Patients in both phases were allowed to continue study treatment until 
disease progression, unacceptable toxicity, or withdrawal of consent.  
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Safety and Efficacy Assessments 
Patients were monitored for safety throughout the trial and up to 28 days after the last dose of study 
treatment. Adverse events (AE) were assessed according to the Common Terminology Criteria for 
Adverse Events version 3.0. Safety evaluations included monitoring of hematology, blood chemistry, and 
urine, and regular assessment of vital signs, physical condition, body weight, ECOG PS, and cardiac 
monitoring.  
Assessment of response to therapy was made per the investigator, based on standardized criteria 
proposed by the international working groups for AML19 and for MDS and CMML.20 Response during 
study treatment was evaluated via blood and bone marrow assessment. Bone marrow aspiration and/or 
core biopsy was obtained within 5 days of the planned end of even-numbered cycles, at the end of 
treatment visit, and at the discretion of the investigator. Peripheral blood assessments were performed 
within 5 days of bone marrow aspiration/biopsy, unless not clinically feasible.  
Bone marrow aspirate samples were collected at screening from patients in phase 2b and sent for next-
generation sequencing analysis (NGS; Genoptix, Carlsbad, CA). Genomic DNA was isolated from the 
samples, and the coding regions of 24 genes (Supplementary Table 1) were amplified by polymerase 
chain reaction and sequenced using NGS technology (MiSeq system; Illumina, Inc, San Diego, CA). 
Somatic mutations consistent with AML, MDS, or myeloproliferative neoplasms were identified.This 
study is registered at http://clinicaltrials.gov as NCT00946647. 
Statistical Analysis 
An adaptive BLRM and dose-escalation criteriasimilar to that proposed by Babb, Rogatko, and Zacks, 
including the escalation with overdose control principle,21 was used to guide dose escalation in phase 
1b. The study was not designed for hypothesis testing of comparisons between the treatment arms. 
Point estimates and 95% exact binomial CIs22 were computed to provide descriptive summaries of 
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response rates. The 1-year survival probabilities were estimated from the Kaplan-Meier curve. All 
analyses were done using SAS software (version 9.3) and R software (version 2.13). 
Results 
Patients and Disposition 
A total of 113 patients were enrolled in the study with a data cutoff for this analysis of April 30, 2014. In 
phase 1b, 31 patients (median age, 69 years; Table 1) receivedPANin dosing cohorts of 20 mg (n=6), 30 
mg (n=18), and 40 mg (n=7). At the time of data cutoff, 4 patients remained on treatment (30 mg [n=3]; 
40 mg [n=1]). Patients in phase 1b had diagnoses of MDS (n=16), CMML (n=4), and AML (n=11). The 
majority of patients with MDS were previously untreated (81.3%), categorized as IPSS intermediate-2 
(87.5%) or high risk (12.5%) at study entry, and had favorable cytogenetics per IPSS (62.5%); 12.5% had 
unfavorable cytogenetics. Among the patients with CMML, 75% were previously untreated. All patients 
with AML were previously untreated for AML; 72.7% had prior MDS that transformed to AML, and 1 of 
these patients received prior treatment with lenalidomide for MDS. A majority of patients with 
AML(54.5%) had unfavorable cytogenetics; the remaining 45.5% had intermediate cytogenetic risk. The 
median time from initial diagnosis to study entry for patients with MDS, CMML, and AML was 1.3 
months (range, 0.5-37.9 months), 1.8 months (range, 0.8-3.2 months), and 0.7 months (range, 0.2-2.5 
months), respectively. Most patients had an initial ECOG PS of either 0 (41.9%) or 1 (48.4%). A summary 
of demographics and baseline characteristics for patients in phase 1b is presented in Table 1. 
A total of 82 patients (median age, 71 years) were enrolled in phase 2b and randomized to receive 
treatment with PAN+AZA (n=40) or AZA (n=42). At the time of data cutoff, 13 patients remained on 
treatment (PAN+AZA [n=7]; AZA [n=6]). Of the 82 phase 2b patients, 47 (57.3%), 13 (15.9%), and 22 
(26.8%) had a diagnosis of MDS, CMML, and AML, respectively. The majority of patients with MDS were 
previously untreated (89.4%), and 44.7% had unfavorable cytogenetics (patients with favorable and 
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intermediate cytogenetics accounted for 27.7% each). Patients with CMML were primarily untreated 
(84.6%), andnearly all patients with AML (95.5%) were previously untreated for AML. Most patients with 
AML had multilineage dysplasia with 21% to 30% bone marrow blasts (95.5%), with 77.3% of these 
patients having prior MDS that transformed to AML and most (81.8%) having intermediate or high 
cytogenetic risk. ECOG PS at baseline was primarily 0 (41.5%) or 1 (52.4%). A comparison of 
demographics and baseline characteristics between treatment arms is presented in Table 2. 
Determination of MTD or RP2D 
Of the 31 patients enrolled in phase 1b, 26 were evaluable for MTD determination (20 mg: 5; 30 mg: 14; 
40 mg: 7). A total of 6 DLTs were observed. In the 20-mg cohort, 1 patient experienced a DLT (not 
specified). Three patients in the 30-mg cohort experienced DLTs, which included atrial fibrillation and 
syncope, dehydration and fatigue, and colitis. In the 40-mg cohort, 2 patients experienced DLTs of grade 
3 nausea and vomiting and grade 3 hyperbilirubinemia. The MTD for PAN was not reached. Although 
DLTs were rare, 2 patients (29%) required at least one PAN dose reduction and 1 patient (14%) required 
at least one AZA dose reduction. Based on the BLRM and safety findings, the 30-mg dose was selected as 
the RP2D. 
Safety 
During phase 1bdose escalation, nearly all patients (96.8%) reported at least one grade 3/4 AE, 
regardless of study drug relationship. The most common grade 3/4 AEs (in ≥20% of patients) were 
primarily hematologic, including thrombocytopenia (54.8%), neutropenia (41.9%), anemia (32.3%), and 
febrile neutropenia (29.0%; Table 3). Twenty-one patients(67.7%) required at least onePANdose 
reduction or interruption with no apparent relationship between PAN dose level and frequency of dose 
delay/change, and 17 patients (54.8%) required at least oneAZA dose reduction or interruption. AEs led 
to treatment discontinuation in 38.7% of patients, with febrile neutropenia (6.5%) and atrial fibrillation 
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(6.5%) reported as the most common AEs leading to discontinuation of treatment. Three patients (9.7%) 
died while on treatment (or within 28 days after the end of treatment) from underlying malignancy 
(n=2) and renal insufficiency not attributed to study drug treatment(n=1).  
In phase 2b, a total of 80 randomized patients (38 PAN+AZA; 42 AZA) received at least one dose of study 
treatment and were included in the safety set. The median duration of treatment with PANwas 20.5 
weeks and for AZA was 23.4 weeks in the PAN+AZA arm vs 16.9 weeks in the AZAarm. A summary of 
frequent AEs by treatment group in phase 2b is presented in Table 4. A greater proportion of patients in 
the PAN+AZA arm experienced at least one grade 3/4 AE compared with the AZAarm (97.4% vs 81.0%). 
The most common grade 3/4 AEs with higher incidence in the PAN+AZA arm than the AZA arm were 
thrombocytopenia (55.3% vs 19.0%), febrile neutropenia (31.6% vs 19.0%), and anemia (21.1% vs 
11.9%)). A slightly higher proportion of patients in the PAN+AZA than in the control arm experienced at 
least one serious AE (71.1% vs 64.3%), with febrile neutropenia (26.3% vs 14.3%), pneumonia (18.4% vs 
9.5%), sepsis (7.9% vs 7.1%), thrombocytopenia (7.9% vs 7.1%), sepsis during neutropenia (0% vs 7.1%), 
pyrexia (5.3% vs 0%), and septic shock (5.3% vs 0%) being the most common serious AEs reported in > 
5% of patientsin either arm. Among patients in the PAN+AZA arm, 78.9% required at least onePAN dose 
reduction or interruption and 65.8% required reduction of AZA compared with 71.4% in the AZA arm. 
The most common reasons for PAN dose reduction/interruption were AEs (68.4%) and scheduling 
conflicts (traveling issues, holidays, illness, etc; 57.9%). In the PAN+AZA arm, a relative dose intensity of 
≥ 90% was achieved for PANin only 47.4% of patients and for AZAin 71.1%. In the AZA arm, 73.8% of 
patients had relative dose intensity ≥ 90%. A greater proportion of patients in the PAN+AZA arm 
discontinued treatment due to AEs compared with the control arm (36.8% vs 23.8%). The most common 
AEs leading to treatment discontinuation in the PAN+AZA and AZA arms were febrile neutropenia (5.3% 
vs 0%), sepsis (5.3% vs 2.4%), and septic shock (5.3% vs 0%), respectively. There was a total of 7 on-
treatment deaths (PAN+AZA, n=5 [13.2%]; AZA, n=2 [4.8%]), which all occurred between the first and 
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third cycles of treatment. None of the patients were known to be in response. In the PAN+AZA arm, 1 
patient died due to MDS and 2 patients died due to causes that were suspected by the investigator to be 
related to study treatment (septic shock during grade 4 febrile neutropenia and pulmonary hemorrhage 
during grade 4 thrombocytopenia). Neither of the deaths in the AZA arm was suspected to be due to 
study treatment. 
Early Efficacy 
Phase 1b 
The clinical response rates were 33.0%, 33.0%, and 42.9% in the 20-mg, 30-mg, and 40-mg cohorts, 
respectively. 
Among patients with MDS/CMML across all dose cohorts, a clinical response (CR, BM-CR, partial 
response [PR], or hematologic improvement [HI]) was observed in 6 patients (30.0%; 95% CI, 11.9%-
54.3%), with 2 CRs (10.0%), 2 BM-CRs (10.0%), 1 PR (5.0%), and 1 HI (5.0%). Erythroid and platelet 
responses were observed in 3 patients (15.0%) each, and no patients had a neutrophil response. Two 
patients relapsed following HI. 
Five patients (45.5%; 95% CI, 16.7%-76.6%) with AML showed a clinical response (CR, CRi, PR), including 
2 CRs (18.2%) and 3 CRi’s (27.3%). Treatment failure was observed in 3 patients (27.3%), and best overall 
response was unknown in 3 patients (27.3%). One patient with AML relapsed following CRi. 
Phase 2b 
A higher proportion of patients achieved a composite CR in the PAN+AZA arm (27.5%; 95% CI, 14.6%-
43.9%) vs the AZA arm (14.3%; 95% CI, 5.4%-28.5%), including a slightly higher proportion of patients 
achieving a CR (15.0% vs 9.5%) or achieving a CRi or BM-CR (12.5% vs 4.8% [Table 5]). However, the 
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overall response rate (composite CR + PR + HI) was similar across the 2 arms (PAN+AZA, 37.5%; AZA, 
38.1%).  
For patients with MDS/CMML,the composite CR rate was higher in the PAN+AZA arm vs the control arm 
(29.0% vs 10.3%; Supplementary Table 2). However, the clinical response (41.9% vs 41.4%), erythroid 
response (25.8% vs 31.0%), platelet response (35.5% vs 24.1%), and neutrophil response (19.4% vs 
13.8%) rates were similar across treatment arms. Relapse was reported in 22.6% of all patients in the 
PAN+AZA arm vs 17.2% in the AZA arm. Among patients with AML, the clinical response rate was 22.2% 
(95% CI, 2.8%-60.0%) in the PAN+AZA arm and 30.8% (95% CI, 9.1%-61.4%) in the control 
arm(Supplementary Table 3). 
For the overall phase 2b population, the probability of being progressionfree at 12 months, based on 
Kaplan-Meier analysis, was similar for both treatment arms (PAN+AZA: 70% [95% CI, 40%-90%]; AZA: 
70% [95% CI, 40%-80%]). The 1-year survival, as computed from the Kaplan-Meier analysis of OS, was 
60% (95% CI, 50%-80%) in the PAN+AZA arm vs 70% (95% CI, 50%-80%) in the control arm (Figure 2). 
Bone marrow aspirate samples from 37 patients (45.1%) were collected for NGS; 20 patients were in the 
PAN+AZA arm (7 of whom achieved CR) and 17 were in the AZA arm (0 of whom achieved CR). The 
genes most often mutated in the available samples include SRSF2 (86.5%), which is involved in RNA 
splicing; SETBP1 (75.7%), which plays a role in epigenetics regulation; and TP53 (51.4%), a tumor 
suppressor gene (Figure 3). However, there was no clear evidence ofa relationship between mutations 
and disease status or response.  
Discussion 
In this study, the combination of PANand AZA did not demonstrate a substantial efficacy benefit 
compared with AZA alone in patients with higher-risk MDS, CMML, and AML. Additionally, patients in 
the PAN+AZA arm experienced a higherrate of grade 3/4 AEs. These results were not anticipated based 
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on the strong preclinical evidence supporting combined treatment with PANand demethylating agents.18 
Similar results were found, though, in phase 2 studies of vorinostat plus AZA for higher-risk MDS and 
CMML,23 entinostat plus AZA for MDS and AML,24 pracinostat plus AZA for previously untreated MDS,25 
and valproic acid plus decitabine for MDS and AML.26,27 
While we observed improvements in the composite CR rate, the overall response rates were similar 
between arms, and there was no appreciable benefit in OS with the addition of PAN. One potential 
reason for the lack of survival benefit in the overall population could be the inherent difficulty in 
selecting MDS/AML patient populations likely to derive benefit. Currently, there is no good universally 
acceptedclinical biomarker for response to epigenetic therapy in these indications. A study by Tan et al28 
demonstrated that an elevation of histone H3 and H4 levels of > 50% from baseline following PAN 
treatment strongly correlated with clinical response.However, a number of other studies examining the 
correlation between acetylation levels and response have failed to show an association, potentially due 
to the use of methodology with inherently lower sensitivity.13,29,30 NGS demonstrated higher rates of 
SRSF2 and SETBP1 mutations than previous studies of similar patient populations,31-33 and no clear 
evidence of a relationship between mutations and disease status or response. However, the lack of data 
for patients in the AZA arm who achieved a CR and the small sample size make it difficult to draw any 
conclusions. 
Consideration should also be given to the potential role of the sequence in which DACi and 
hypomethylating agents are administered. Although this concept was reflected in scheduling the 2 
agents, with PAN started on day 3 of each cycle, both agents were in effect given concurrently for a 
substantial part of the first week of each cycle. Results from a phase 1 study showed that concurrent 
administration of vorinostat and decitabine yielded better responses compared with sequential 
administration34; however, PAN has been shown to induce cell cycle arrest,35 which may lead to 
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antagonistic effects when used in combination with AZA in the present schedule. Thus, other doses and 
schedules of this combination may need to be explored.  
Furthermore, tolerability of PAN+AZA could potentially have limited the therapeutic efficacy of this 
combination by preventing delivery of sufficient doses of PANin particular. Only 47.4 % of patients in the 
combination arm received ≥ 90% of the scheduled dose due to dose reductions and interruptions, 
which, for the most part, were AErelated. This is one explanation provided for the lack of benefit of AZA 
plus vorinostat over AZA in the North American Intergroup Study SWOG S1117.23Hematologic toxicity is 
common to both DACi and hypomethylating agents, so the potential for aggravating thrombocytopenia 
and neutropenia by combining these 2 classes of drugs was anticipated when designing the study. Even 
though we did not observe extremely prolonged cytopenia attributable to study drugs, hematologic 
toxicity wasthe principal reason for decreasing drug dose and interrupting or discontinuing treatment. In 
contrast, gastrointestinal and constitutional AEs were generally well managed and did not constitute a 
major management problem during the DLT-defining period, so that the number of DLTs in all dose 
cohorts in phase 1b was below the threshold for declaration of MTD. The overall long-term safety profile 
of the regimen in this study posed a challenge, with nearly all patients in the PAN+AZA arm of phase 2b 
(97.3%) reporting at least one grade 3/4 AE vs 81.0% in the AZA arm. Common AEs (≥ 50% in PAN+AZA 
arm) were nausea, thrombocytopenia, diarrhea, and pyrexia, consistent with the established safety 
profile of both drugs as singleagents in patients with hematologic malignancies.6,10,36 Grade 3/4 AEs were 
primarily managed through dose reduction/interruption, leading to only moderate drug-related 
discontinuations. However, the observed safety profile was similar to AZA in combination with other, 
less potent, DACi’s.13,29,37-40 Additionally, in phase 2b, there was a higher rate of on-treatment mortality 
in the PAN+AZA arm compared with the AZA arm,and the death of 2 of 5 patients in the PAN+AZA arm 
was suspected by the investigator to be related to study drug treatment.  
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The anticipation of clinical benefit in the present study was based on compelling preliminary data from 
an uncontrolled phase 1b/2 trial examining PAN+AZA in patients with higher-risk MDS and AML, which 
demonstrated an overall response rate of 31% (9/29) for patients with AML and 50% (5/10) for patients 
with high-risk MDS at the MTD of PAN30 mg plus AZA75 mg/m2.28 The observed safety profile was 
similar to the present study, with high rates of grade 3/4 hematologic AEs including neutropenia 
(96.2%), thrombocytopenia (91.7%), and anemia (88.9%). As in the previous study, the present trial 
demonstrated better clinical response in patients with MDS/CMML compared with those with AML. In 
patients with AML, the addition of PANdid not enhance the clinical benefit of AZA.In patients with 
MDS/CMML, the composite CR rate was nearly 3 times higher in the PAN+AZA arm (29.0%vs 
10.3%).However, as already discussed, there was no OS benefit. There are a number of factors that 
could have contributed to this. For example, patients may not have stayed on treatment long enough to 
improve their OS; composite CR may be a poor correlate to OS; the overall response rate, which was 
similar between the 2 arms, may have a greater influence on OS than composite CR; and the study may 
have been underpowered for OS.All together, these results suggest that PAN+AZA could provide clinical 
benefit in select subsets of patients (ie, patients with high-risk MDS); however, further research would 
be warranted in specific subpopulations. 
The results of the present study demonstrate that the regimen of PAN 30 mg plus AZA75 mg/m2 has an 
unfavorable risk/benefit profile in patients with MDS, CMML, or AML. The development of a consistent 
biomarker for patients withMDS/AML likely to respond to DACi could help shift the risk/benefit 
relationship of this type of regimen. However, in the current therapeutic landscape, further dose and 
schedule optimization would be warranted to improve the tolerability of the combination in this patient 
population. It is worth noting that at the time of data cutoff (April 30, 2014), 3 patients from phase 1b 
and 13 patients from phase 2b (PAN+AZA [n=7]; AZA [n=6]) remained on treatment, with most of the 
patients having achieved CR. 
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Table 1. Demographics and Baseline Characteristics of Patients Enrolled in the Phase 1b Portion by 
Initial Dose Group of PAN 
 PAN+AZA 
20 mg 
n = 6 
PAN+AZA 
30 mg 
n = 18 
PAN+AZA 
40 mg 
n = 7 
All Patients 
 
N =  31 
Median age (range), years  70 (60-80) 70.5 (57-81) 69 (34-79) 69 (34-81) 
Female/male, % 33.3/66.7 55.6/44.4 57.1/42.9 51.6/48.4 
Disease, n (%) 
    MDS 
    CMML 
    AML 
 
5 (83.3) 
1 (16.7) 
0 
 
10 (55.6) 
2 (11.1) 
6 (33.3) 
 
1 (14.3) 
1 (14.3) 
5 (71.4) 
 
16 (51.6) 
4 (12.9) 
11 (35.5) 
ECOG PS, n (%) 
    0 
    1 
    2 
 
2 (33.3) 
3 (50.0) 
1 (16.7) 
 
10 (55.6) 
7 (38.9) 
1 (5.6) 
 
1 (14.3) 
5 (71.4) 
1 (14.3) 
 
13 (41.9) 
15 (48.4) 
3 (9.7) 
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Table 2. Demographics and Baseline Characteristics of Patients Enrolled in the Phase 2b Portion by 
Treatment Group 
 PAN+AZA 
n = 40 
AZA 
n = 42 
All Patients 
N = 82 
Median age (range), years  68 (44-81) 72 (42-85) 71 (42-85) 
Female/male, % 27.5/72.5 40.5/59.5 34.1/65.9 
Disease, n (%) 
    MDS 
    CMML 
    AML 
 
25 (62.5) 
6 (15.0) 
9 (22.5) 
 
22 (52.4) 
7 (16.7) 
13 (31.0) 
 
47 (57.3) 
13 (15.9) 
22 (26.8) 
ECOG PS, n (%) 
    0 
    1 
    2 
 
14 (35.0) 
25 (62.5) 
1 (2.5) 
 
20 (47.6) 
18 (42.9) 
4 (9.5) 
 
34 (41.5) 
43 (52.4) 
5 (6.1) 
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Table 3. Frequent AEs (≥ 20%) Regardless of Study Drug Relationship by Initial Dose Group of PAN in 
the Phase 1b Portion 
 PAN+AZA 
20 mg 
n = 6 
PAN+AZA 
30 mg 
n = 18 
PAN+AZA 
40 mg 
n = 7 
All Patients 
 
N = 31 
 All 
grades,  
n (%) 
Grades 
3/4,  
n (%) 
All 
grades,  
n (%) 
Grades 
3/4,  
n (%) 
All 
grades,  
n (%) 
Grades 
3/4,  
n (%) 
All 
grades,  
n (%) 
Grades 
3/4,  
n (%) 
Nausea 4 (66.7) 0 14 (77.8) 3 (16.7) 7 (100.0) 1 (14.3) 25 (80.6) 4 (12.9) 
Diarrhea 4 (66.7) 1 (16.7) 15 (83.3) 1 (5.6) 4 (57.1) 0 23 (74.2) 2 (6.5) 
Fatigue 4 (66.7) 0 13 (72.2) 4 (22.2) 5 (71.4) 0 22 (71.0) 4 (12.9) 
Thrombocytopenia 3 (50.0) 2 (33.3) 12 (66.7) 11 (61.1) 5 (71.4) 4 (57.1) 20 (64.5) 17 (54.8) 
Vomiting 5 (83.3) 0 9 (50.0) 2 (11.1) 4 (57.1) 1 (14.3) 18 (58.1) 3 (9.7) 
Constipation 2 (33.3) 0 11 (61.1) 1 (5.6) 3 (42.9) 0 16 (51.6) 1 (3.2) 
Neutropenia 2 (33.3) 2 (33.3) 9 (50.0) 8 (44.4) 3 (42.9) 3 (42.9) 14 (45.2) 13 (41.9) 
Decreased 
appetite 
3 (50.0) 0 6 (33.3) 0 5 (71.4) 0 14 (45.2) 0 
Anemia 2 (33.3) 1 (16.7) 8 (44.4) 6 (33.3) 3 (42.9) 3 (42.9) 13 (41.9) 10 (32.3) 
Pyrexia 2 (33.3) 0 7 (38.9) 1 (5.6) 4 (57.1) 0 13 (41.9) 1 (3.2) 
Hypokalemia 1 (16.7) 1 (16.7) 9 (50.0) 4 (22.2) 3 (42.9) 0 13 (41.9) 5 (16.1) 
Asthenia 3 (50.0) 1 (16.7) 6 (33.3) 0 3 (42.9) 2 (28.6) 12 (38.7) 3 (9.7) 
Hypocalcemia 3 (50.0) 0 7 (38.9)  1 (5.6) 1 (14.3) 0 11 (35.5) 1 (3.2) 
Febrile 
neutropenia 
2 (33.3) 2 (33.3) 6 (33.3) 5 (27.8) 2 (28.6) 2 (28.6) 10 (32.3) 9 (29.0) 
Blood creatinine 
increased 
1 (16.7) 0 5 (27.8) 0 4 (57.1) 1 (14.3) 10 (32.3) 1 (3.2) 
Dyspnea 3 (50.0)  1 (16.7) 5 (27.8) 0 2 (28.6) 1 (14.3) 10 (32.3) 2 (6.5) 
Abdominal pain 3 (50.0) 0 5 (27.8) 0 1 (14.3) 0 9 (29.0) 0 
Edema peripheral 2 (33.3) 0 4 (22.2) 0 3 (42.9) 0 9 (29.0) 0 
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Table 4. Frequent AEs (≥ 15%) Regardless of Study Drug Relationship by Treatment Group in the Phase 2b Portion  
 PAN+AZA 
n = 38a 
AZA 
n = 42a 
All Patients 
N = 80 
 All grades,  
n (%) 
Grades 3/4,  
n (%) 
All grades,  
n (%) 
Grades 3/4,  
n (%) 
All grades,  
n (%) 
Grades 3/4,  
n (%) 
Nausea 23 (60.5) 4 (10.5) 18 (42.9) 1 (2.4) 41 (51.3) 5 (6.3) 
Thrombocytopenia 21 (55.3) 21 (55.3) 11 (26.2) 8 (19.0) 32 (40.0) 29 (36.3) 
Diarrhea 19 (50.0) 3 (7.9) 9 (21.4) 1 (2.4) 28 (35.0) 4 (5.0) 
Neutropenia 16 (42.1) 16 (42.1) 11 (26.2) 11 (26.2) 27 (33.8) 27 (33.8) 
Vomiting 16 (42.1) 3 (7.9) 11 (26.2) 1 (2.4) 27 (33.8) 4 (5.0) 
Pyrexia 19 (50.0) 2 (5.3) 8 (19.0) 1 (2.4) 27 (33.8) 3 (3.8) 
Anemia 12 (31.6) 8 (21.1) 13 (31.0) 5 (11.9) 25 (31.3) 13 (16.3) 
Constipation 10 (26.3) 2 (5.3) 15 (35.7) 0 25 (31.3) 2 (2.5) 
Fatigue 8 (21.1) 2 (5.3) 16 (38.1) 0 24 (30.0) 2 (2.5) 
Febrile neutropenia 13 (34.2) 12 (31.6) 8 (19.0) 8 (19.0) 21 (26.3) 20 (25.0) 
Edema peripheral 8 (21.1) 0 8 (19.0) 0 16 (20.0) 0 
Decreased appetite 10 (26.3) 2 (5.3) 6 (14.3) 0 16 (20.0) 2 (2.5) 
Asthenia 8 (21.1) 1 (2.6) 6 (14.3) 0 14 (17.5) 1 (1.3) 
Pneumonia 8 (21.1) 6 (15.8) 6 (14.3) 5 (11.9) 14 (17.5) 11 (13.8) 
Headache 6 (15.8) 0 7 (16.7) 2 (4.8) 13 (16.3) 2 (2.5) 
Epistaxis 6 (15.8) 1 (2.6) 6 (14.3) 0 12 (15.0) 1 (1.3) 
26 
 
Hypokalemia 6 (15.8) 4 (10.5) 6 (14.3) 1 (2.4) 12 (15.0) 5 (6.3) 
Weight decreased 7 (18.4) 0 4 (9.5) 0 11 (13.8) 0 
Cough 6 (15.8) 0 5 (11.9) 0 11 (13.8) 0 
Platelet count decreased 7 (18.4) 5 (13.2) 2 (4.8) 2 (4.8) 9 (11.3) 7 (8.8) 
Abdominal pain 6 (15.8) 1 (2.6) 1 (2.4) 0 7 (8.8) 1 (1.3) 
a Two patients enrolled in the AZA arm did not receive medication. In addition, 2 patients enrolled in the PAN+AZA arm received only AZA and 
were therefore included in the AZA group for analysis. 
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Table 5. Early Efficacy in the Phase 2b Portion 
 
Best Response 
PAN+AZA 
n = 40 
AZA 
n = 42 
All Patients 
N = 82 
Composite CR, n (%)  
(95% CI) 
11 (27.5)  
(14.6-43.9) 
6 (14.3)  
(5.4-28.5) 
17 (20.7)  
(12.6-31.1) 
    CR, n (%) 6 (15.0) 4 (9.5) 10 (12.2) 
    BM-CR (MDS/CMML) or CRi (AML), n (%) 5 (12.5) 2 (4.8) 7 (8.5) 
Median time to progression (95% CI), months       NE (11.1-NE) 15.2 (11.0-NE) NE (12.7-NE) 
Median OS (95% CI), months  14.9 (10.4-NE) 15.6 (11.4-NE) 15.4 (13.0-NE) 
Abbreviation: NE, not estimable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 28 
 
Figure Legends 
 
Figure 1. Study design.In phase 1b, patients received escalating doses of PAN in combination with AZA 
in phase 1b. In phase 2b, patients were randomized to receive treatment with either the RP2D of 
PAN+AZA or single-agent AZA. 
 
Figure 2. OS analysis.Kaplan-Meier curves are shown for patients randomized to receive PAN+AZA 
versus AZA alone. Symbols represent censoring times for patients in the PAN+AZA (squares) or AZA 
(triangles) arms, respectively. 
Figure 3. NGS analysis.Patients with NGS data are from phase 2b. A gene is considered to be mutant 
(MT) if one or more alterations, regardless of functional significance, are detected.  
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Figure 3.  
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Supplementary Table 1. Genes Sequenced via Next-Generation Sequencing in the Phase 2b Portion 
 Gene Exons 
RNA splicing SF3B1 13-16 
SRSF2 1 
U2AF1 2, 6 
ZRSR2 2-5, 7-11 
Epigenetic ASXL1 12-13 
DNMT3A 7-22 
EZH2 1-19 
IDH1 2 
IDH2 4 
SETBP1 3 
TET2 1-9 
Transcription factors ETV6 1-8 
PHF6 1-9 
RUNX1 3-8 
Activated signaling CBL 7-9 
JAK2 10-12 
KIT 8-11, 13, 17-18 
MPL 10-11 
NRAS 1, 2 
Other CALR 9 
CSF3R 1-15 
FLT3 14, 20, no ITD 
NPM1 10-11 
TP53 1-10 
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Supplementary Table 2. Best Overall Response for Patients With MDS/CMML in the Phase 2b Portion 
 
Best Response 
PAN+AZA 
n = 31 
AZA 
n = 29 
All Patients 
n = 60 
Clinical response (CR, BM-CR, PR),  
n (%) (95% CI) 
13 (41.9)  
(24.5-60.9) 
12 (41.4)  
(23.5-61.1) 
25 (41.7)  
(29.1-55.1) 
    CR, n (%) 5 (16.1) 2 (6.9) 7 (11.9) 
    BM-CR, n (%) 4 (12.9) 1 (3.4) 5 (8.3) 
    PR, n (%) 0 2 (6.9) 2 (3.3) 
    SD, n (%) 5 (16.1) 5 (17.2) 10 (16.7) 
    Disease progression, n (%) 1 (3.2) 3 (10.3) 4 (6.7) 
    Unknown, n (%) 16 (51.6) 16 (55.2) 32 (53.3) 
Relapse, n (%) 2 (6.5) 0 2 (3.3) 
    Relapse after CR, n (%) 1 (3.2) 0 1 (3.2) 
    Relapse after BM-CR,n (%) 1 (3.2) 0 1 (3.2) 
    Relapse after PR, n (%) 0 0 0 
Abbreviations:AZA, azacitidine; BM-CR, bone marrow complete response; CR, complete response; PAN, 
panobinostat; PR, partial response; SD, stable disease. 
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Supplementary Table 3. Best Overall Response for Patients With AML in the Phase 2b Portion 
 
Best Response 
PAN+AZA 
n = 9 
AZA 
n = 13 
All Patients 
n = 22 
Clinical response (CR, BM-CR, PR, HI),  
n (%) (95% CI) 
2 (22.2)  
(2.8-60.0) 
4 (30.8)  
(9.1-61.4) 
6 (27.3)  
(10.7-50.2) 
    CR, n (%) 1 (11.1) 2 (15.4) 3 (13.6) 
    CRi, n (%) 1 (11.1) 1 (7.7) 2 (9.1) 
    PR, n (%) 0 1 (7.7) 1 (4.5) 
    Treatment failure, n (%) 4 (44.4) 6 (46.2) 10 (45.5) 
    Unknown, n (%) 3 (33.3) 3 (23.1) 6 (27.3) 
Relapse, n (%) 0 5 (38.5) 5 (22.7) 
    Relapse after CR, n (%) 0 2 (15.4) 2 (9.1) 
    Relapse after BM-CR,n (%) 0 1 (7.7) 1 (4.5) 
    Relapse after PR, n (%) 0 1 (7.7) 1 (4.5) 
Abbreviations: CRi,morphologic complete response with incomplete blood count; HI, hematologic 
improvement. 
